What’s the current market cap for Conmed stock?

Conmed (CNMD) has a market cap of $981m as of June 19, 2026.

What is the P/E ratio for Conmed stock?

The price to earnings (P/E) ratio for Conmed (CNMD) stock is 18.41 as of June 19, 2026.

Does Conmed stock pay dividends?

Yes, the Conmed (CNMD) stock pays dividends to shareholders. As of June 19, 2026, the dividend rate is $0.4 and the yield is 2.46%. Conmed has a payout ratio of 33.85% on a trailing twelve-month basis.

When is the next Conmed dividend payment date?

The next Conmed (CNMD) dividend payment date is unconfirmed.

What is the beta indicator for Conmed?

Conmed (CNMD) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Conmed stock | $CNMD Share Price

13:30

15:10

16:45

18:25

20:00

About Conmed

Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.

Ticker

$CNMD

Sector

Health

Primary listing

NYSE

Employees

3,900

Headquarters

Largo, United States

Website

www.conmed.com

Conmed Metrics

BasicAdvanced

$981m

18.41

$1.77

0.94

$0.40

2.46%

What the Analysts think about Conmed

Analyst ratings (Buy, Hold, Sell) for Conmed stock.

Bulls say / Bears say

Conmed delivered adjusted EPS of $0.89 in Q1 2026, beating the consensus estimate of $0.82 by $0.07, highlighting resilient profitability amid strategic portfolio shifts (Investing.com†)

The company preliminarily forecast FY 2026 total reported revenue of $1.345 billion to $1.375 billion and raised its organic constant-currency revenue growth guidance to 5.0%–6.5%, underscoring management’s confidence in underlying demand (Reuters†)

Strategic divestiture of the GI portfolio sharpened focus on high-margin platforms—AirSeal, Buffalo Filter, BioBrace—which helped expand adjusted gross margin by 100 basis points to 57.4% in Q1 (Investing.com†)

Reported Q1 revenue declined 1.3% year-over-year to $317.0 million, driven by a $15.5 million headwind from the divestiture of its gastroenterology product lines (Business Wire†)

Data summarised monthly by Lightyear AI. Last updated on 30 May 2026.

Conmed Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Conmed Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Conmed delivered adjusted EPS of $0.89 in Q1 2026, beating the consensus estimate of $0.82 by $0.07, highlighting resilient profitability amid strategic portfolio shifts (Investing.com†)

Reported Q1 revenue declined 1.3% year-over-year to $317.0 million, driven by a $15.5 million headwind from the divestiture of its gastroenterology product lines (Business Wire†)

Data summarised monthly by Lightyear AI. Last updated on 30 May 2026.